Received Jul 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y015108 | — |
No additional AE; HCP called to report a temperature excursion for VARIVAX and PROQUAD. HCP reported that VARIVAX and PROQUAD were administered to multiple patients on multiple dates after being improperly stored. This case pertains to one patient who received imprope; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 18-Jun-2025, the was vaccinated with improper storage dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), formulation: injection, lot #Y015108, expiration date: 06-Sep-2026, 0.5 mL (route of administration and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT). On an unknown date, administered dose of vaccine was exposed to the temperature excursion of 6.3 degrees Fahrenheit (F) for 16 minutes (product storage error). No additional adverse event reported (no adverse event). This is one of several reports received from the same reporter.
Sterile diluent